Enclomiphene vs Progesterone
A side-by-side research comparison of Enclomiphene and Progesterone across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Enclomiphene | Progesterone |
|---|---|---|
| Full name | Enclomiphene Citrate | Micronized Progesterone (Prometrium) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | Investigational drug | FDA Approved |
| Mechanism | Blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing GnRH pulsatility, which stimulates LH and FSH release for endogenous testosterone production. | Agonizes progesterone receptors and GABA-A receptors (via allopregnanolone metabolite). Inhibits 5-alpha reductase, opposes estrogen proliferative effects, and promotes myelination in neural tissue. |
| Molecular weight | 598.09 Da | 314.46 Da |
| Half-life | 10-14 hours | ~16-18 hours (oral micronized) |
| Bioavailability | ~50% oral | ~10% oral (first-pass); ~100% topical/vaginal |
| Typical dose | 12.5-25 mg | 100-200 mg oral or 20-40 mg topical |
| Frequency | Daily | Nightly (oral) or daily (topical) |
| Route | Oral capsule | Oral capsule, topical cream, or vaginal |
Enclomiphene reported benefits
- Increased endogenous testosterone
- Preserved fertility
- Improved libido
- Enhanced energy and mood
- No testicular atrophy
Progesterone reported benefits
- Enhanced deep sleep (GABA modulation)
- Neuroprotection
- Estrogen opposition
- Reduced anxiety
- DHT reduction (5AR inhibition)
- Cardiovascular protection
Related comparisons
Research and educational reference only. Not medical advice.